calcmedical

Lidocaine and Epinephrine Dental Dose Calculator

Lidocaine HCl 2% (20 mg/mL) and epinephrine, dental injection. Brands: Xylocaine Dental, Lignospan, Flavalta, and supplier labels. From 18 FDA labels and the AAPD guideline.

Draft for the site pharmacist's review, Nov 15, 2026.

Lidocaine and Epinephrine for Newborns (Neonates, 0 to 28 Days)

No standard dose

No dose is shown for newborns. The labels give no information specific to this age, so the page takes the safer choice.

AAPD, for information only: "Doses of amides should be decreased by 30% in infants younger than 6 months." (AAPD 2023, Table note B)

Lidocaine and Epinephrine for Infants (1 to 12 Months)

No standard dose

No dose is shown for infants. The labels give no information specific to this age, so the page takes the safer choice.

AAPD, for information only: "Doses of amides should be decreased by 30% in infants younger than 6 months." (AAPD 2023, Table note B)

Lidocaine and Epinephrine Dose for Children 1 to 9 Years

Max 4.4 mg/kg lidocaine (AAPD), never over 7 mg/kg

Special situations, children 1 to 9

With kidney disease

No dose change in the labels. Metabolites may build up.

"Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites." (Flavalta 12.3)

With liver disease

Consider a lower dose and closer monitoring in moderate to severe liver disease. The label gives no number.

"...consider reduced dosing and increased monitoring for local anesthetic systemic toxicity in patients with moderate to severe hepatic impairment..." (Flavalta 8.6)

On dialysis

Not covered by the labels.

The labels do not mention dialysis.

With heart disease

Give reduced doses. A conservative epinephrine limit is applied below. It is expert guidance, not a label or guideline limit.

"...should also be given in reduced doses in patients with impaired cardiovascular function (e.g., hypotension, heart block)..." (Flavalta 5.6) · "A dose of 40 µg ... is the most conservative and frequently cited dose limitation for epinephrine in patients with significant cardiovascular disease. It should be clarified that this guideline more accurately reflects 30-minute time periods, not appointments." (Becker 2006)

Taking interacting medicines

No dose change in the labels. Avoid if possible, otherwise monitor closely. MAO inhibitors, tricyclic antidepressants and nonselective beta blockers can cause severe high blood pressure. Ergot-type oxytocics can cause severe high blood pressure or stroke. Phenothiazines and butyrophenones can reduce or reverse the effect of epinephrine.

"Concurrent use of these agents should generally be avoided." (Flavalta 7.2, 7.4, 7.7) · "Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs" (Flavalta 7.3)

At risk of methemoglobinemia

No dose change in the labels. Monitor closely when other oxidizing drugs are given, including other local anesthetics, nitrates, dapsone and sulfonamides.

"Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics" (Flavalta 7.5)

Sulfite allergy

Contains a sulfite (potassium metabisulfite in Flavalta).

"...such as the sulfites in epinephrine-containing solutions" (Flavalta 17)

Lidocaine and Epinephrine Dose for Children 10 to 16 Years

Max 4.4 mg/kg lidocaine (AAPD), never over 7 mg/kg or 500 mg

Special situations, children 10 to 16

With kidney disease

No dose change in the labels. Metabolites may build up.

"Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites." (Flavalta 12.3)

With liver disease

Consider a lower dose and closer monitoring in moderate to severe liver disease. The label gives no number.

"...consider reduced dosing and increased monitoring for local anesthetic systemic toxicity in patients with moderate to severe hepatic impairment..." (Flavalta 8.6)

On dialysis

Not covered by the labels.

The labels do not mention dialysis.

With heart disease

Give reduced doses. A conservative epinephrine limit is applied below. It is expert guidance, not a label or guideline limit.

"...should also be given in reduced doses in patients with impaired cardiovascular function (e.g., hypotension, heart block)..." (Flavalta 5.6) · "A dose of 40 µg ... is the most conservative and frequently cited dose limitation for epinephrine in patients with significant cardiovascular disease. It should be clarified that this guideline more accurately reflects 30-minute time periods, not appointments." (Becker 2006)

Taking interacting medicines

No dose change in the labels. Avoid if possible, otherwise monitor closely. MAO inhibitors, tricyclic antidepressants and nonselective beta blockers can cause severe high blood pressure. Ergot-type oxytocics can cause severe high blood pressure or stroke. Phenothiazines and butyrophenones can reduce or reverse the effect of epinephrine.

"Concurrent use of these agents should generally be avoided." (Flavalta 7.2, 7.4, 7.7) · "Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs" (Flavalta 7.3)

At risk of methemoglobinemia

No dose change in the labels. Monitor closely when other oxidizing drugs are given, including other local anesthetics, nitrates, dapsone and sulfonamides.

"Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics" (Flavalta 7.5)

Sulfite allergy

Contains a sulfite (potassium metabisulfite in Flavalta).

"...such as the sulfites in epinephrine-containing solutions" (Flavalta 17)

In pregnancy

No dose change in the labels.

"Available published data and decades of clinical use with lidocaine in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes." (Flavalta 8.1)

While breastfeeding

No dose change in the labels. Lidocaine passes into milk in low amounts and is poorly absorbed by mouth.

"Published data report the presence of lidocaine and its metabolites in human milk in low amounts, along with poor oral bioavailability." (Flavalta 8.2)

Lidocaine and Epinephrine Dose for Adults (17 to 64)

Max 7 mg/kg lidocaine, never over 500 mg, healthy adults

Special situations, adults

With kidney disease

No dose change in the labels. Metabolites may build up.

"Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites." (Flavalta 12.3)

With liver disease

Consider a lower dose and closer monitoring in moderate to severe liver disease. The label gives no number.

"...consider reduced dosing and increased monitoring for local anesthetic systemic toxicity in patients with moderate to severe hepatic impairment..." (Flavalta 8.6)

On dialysis

Not covered by the labels.

The labels do not mention dialysis.

With heart disease

Give reduced doses. A conservative epinephrine limit is applied below. It is expert guidance, not a label or guideline limit.

"...should also be given in reduced doses in patients with impaired cardiovascular function (e.g., hypotension, heart block)..." (Flavalta 5.6) · "A dose of 40 µg ... is the most conservative and frequently cited dose limitation for epinephrine in patients with significant cardiovascular disease. It should be clarified that this guideline more accurately reflects 30-minute time periods, not appointments." (Becker 2006)

Taking interacting medicines

No dose change in the labels. Avoid if possible, otherwise monitor closely. MAO inhibitors, tricyclic antidepressants and nonselective beta blockers can cause severe high blood pressure. Ergot-type oxytocics can cause severe high blood pressure or stroke. Phenothiazines and butyrophenones can reduce or reverse the effect of epinephrine.

"Concurrent use of these agents should generally be avoided." (Flavalta 7.2, 7.4, 7.7) · "Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs" (Flavalta 7.3)

At risk of methemoglobinemia

No dose change in the labels. Monitor closely when other oxidizing drugs are given, including other local anesthetics, nitrates, dapsone and sulfonamides.

"Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics" (Flavalta 7.5)

Sulfite allergy

Contains a sulfite (potassium metabisulfite in Flavalta).

"...such as the sulfites in epinephrine-containing solutions" (Flavalta 17)

In pregnancy

No dose change in the labels.

"Available published data and decades of clinical use with lidocaine in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes." (Flavalta 8.1)

While breastfeeding

No dose change in the labels. Lidocaine passes into milk in low amounts and is poorly absorbed by mouth.

"Published data report the presence of lidocaine and its metabolites in human milk in low amounts, along with poor oral bioavailability." (Flavalta 8.2)

Lidocaine and Epinephrine Dose for Older Adults (65 and Older)

Max 7 mg/kg lidocaine, never over 500 mg, reduced doses advised

Special situations, older adults

With kidney disease

No dose change in the labels. Metabolites may build up.

"Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites." (Flavalta 12.3)

With liver disease

Consider a lower dose and closer monitoring in moderate to severe liver disease. The label gives no number.

"...consider reduced dosing and increased monitoring for local anesthetic systemic toxicity in patients with moderate to severe hepatic impairment..." (Flavalta 8.6)

On dialysis

Not covered by the labels.

The labels do not mention dialysis.

With heart disease

Give reduced doses. A conservative epinephrine limit is applied below. It is expert guidance, not a label or guideline limit.

"...should also be given in reduced doses in patients with impaired cardiovascular function (e.g., hypotension, heart block)..." (Flavalta 5.6) · "A dose of 40 µg ... is the most conservative and frequently cited dose limitation for epinephrine in patients with significant cardiovascular disease. It should be clarified that this guideline more accurately reflects 30-minute time periods, not appointments." (Becker 2006)

Taking interacting medicines

No dose change in the labels. Avoid if possible, otherwise monitor closely. MAO inhibitors, tricyclic antidepressants and nonselective beta blockers can cause severe high blood pressure. Ergot-type oxytocics can cause severe high blood pressure or stroke. Phenothiazines and butyrophenones can reduce or reverse the effect of epinephrine.

"Concurrent use of these agents should generally be avoided." (Flavalta 7.2, 7.4, 7.7) · "Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs" (Flavalta 7.3)

At risk of methemoglobinemia

No dose change in the labels. Monitor closely when other oxidizing drugs are given, including other local anesthetics, nitrates, dapsone and sulfonamides.

"Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics" (Flavalta 7.5)

Sulfite allergy

Contains a sulfite (potassium metabisulfite in Flavalta).

"...such as the sulfites in epinephrine-containing solutions" (Flavalta 17)

Sources

18 FDA labels, AAPD 2023, Becker 2006

What each number comes from

7 mg/kg and 500 mg
Every dental label: "kept below 500 mg" and never over "7 mg/kg" of body weight (Flavalta 2.2; same in Xylocaine Dental).
4.4 mg/kg, children
"The table lists the long-established pediatric dental maximum dose of lidocaine as 4.4 mg/kg; however, the MRD is 7 mg/kg." (AAPD 2023, Table note C)
20 mg/mL
Lidocaine HCl 2%, every listing in the FDA NDC Directory.
0.01 and 0.02 mg/mL
Epinephrine 1:100,000 and 1:50,000, FDA NDC Directory.
0.04 mg epinephrine
Conservative limit with significant heart disease, per 30 minutes (Becker and Reed 2006). Not an AHA limit. Its origin is a textbook (Davis 2010, J Can Dent Assoc).
Two anesthetics
Maximums add up (Becker and Reed 2006). No guideline body publishes a formula.
Retrieved
Nov 15, 2026. All 18 labels active in the FDA NDC Directory.

All 18 dental labels checked

Same limits in all of them. Flavalta (Mar 2026) is the newest format and is cited by section number.

Not used here

7 lidocaine and epinephrine vials and ampules for general injection (Hospira and others). Their dosing differs, so they get their own page.